175 related articles for article (PubMed ID: 26891067)
1. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
[TBL] [Abstract][Full Text] [Related]
2. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
[TBL] [Abstract][Full Text] [Related]
3. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.
Douer D
Oncologist; 2016 Jul; 21(7):840-7. PubMed ID: 27328933
[TBL] [Abstract][Full Text] [Related]
7. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
Silverman JA; Deitcher SR
Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
[TBL] [Abstract][Full Text] [Related]
8. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
Deitcher OR; Glaspy J; Gonzalez R; Sato T; Bedikian AY; Segarini K; Silverman J; Deitcher SR
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):197-202. PubMed ID: 24417913
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
[TBL] [Abstract][Full Text] [Related]
10. Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia.
Harrison TS; Lyseng-Williamson KA
BioDrugs; 2013 Feb; 27(1):69-74. PubMed ID: 23329395
[TBL] [Abstract][Full Text] [Related]
11. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
Schiller GJ; Damon LE; Coutre SE; Hsu P; Bhat G; Douer D
J Adolesc Young Adult Oncol; 2018 Oct; 7(5):546-552. PubMed ID: 30239252
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.
Kaplan LD; Deitcher SR; Silverman JA; Morgan G
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):37-42. PubMed ID: 24252360
[TBL] [Abstract][Full Text] [Related]
14. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
Rodriguez MA; Pytlik R; Kozak T; Chhanabhai M; Gascoyne R; Lu B; Deitcher SR; Winter JN;
Cancer; 2009 Aug; 115(15):3475-82. PubMed ID: 19536896
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
Bedikian AY; Silverman JA; Papadopoulos NE; Kim KB; Hagey AE; Vardeleon A; Hwu WJ; Homsi J; Davies M; Hwu P
J Clin Pharmacol; 2011 Aug; 51(8):1205-12. PubMed ID: 20978276
[TBL] [Abstract][Full Text] [Related]
16. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
Davis T; Farag SS
Int J Nanomedicine; 2013; 8():3479-88. PubMed ID: 24072970
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
18. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.
Raj TA; Smith AM; Moore AS
Int J Nanomedicine; 2013; 8():4361-9. PubMed ID: 24232122
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
20. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
Ollila T; Butera J; Egan P; Reagan J; Thomas A; Yakirevich I; MacKinnon K; Margolis J; McMahon J; Rosati V; Olszewski AJ
Oncologist; 2022 Jul; 27(7):532-e542. PubMed ID: 35641232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
